{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "CMV infection in pregnancy",
      "CMV screening in pregnancy",
      "Congenital cytomegalovirus infection",
      "fetal therapy",
      "hyperimmune globulin",
      "immunoglobulin therapy"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29072089",
  "DateCompleted": {
    "Year": "2018",
    "Month": "06",
    "Day": "26"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "12",
    "Day": "02"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2017",
        "Month": "11",
        "Day": "06"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1080/14787210.2017.1398081"
    ],
    "Journal": {
      "ISSN": "1744-8336",
      "JournalIssue": {
        "Volume": "15",
        "Issue": "11",
        "PubDate": {
          "Year": "2017",
          "Month": "Nov"
        }
      },
      "Title": "Expert review of anti-infective therapy",
      "ISOAbbreviation": "Expert Rev Anti Infect Ther"
    },
    "ArticleTitle": "Hyperimmune globulin in pregnancy for the prevention of congenital cytomegalovirus disease.",
    "Pagination": {
      "StartPage": "977",
      "EndPage": "986",
      "MedlinePgn": "977-986"
    },
    "Abstract": {
      "AbstractText": [
        "Cytomegalovirus (CMV) is the most common and serious cause of congenital infections in developed countries since it is capable of infecting the fetus after both primary and recurrent maternal infection, and can be spread for years by infected children. Areas covered: Animal and human pregnancy studies about the prevention of congenital CMV infection and disease by CMV-specific hyperimmune globulin (HIG). Commercial HIG is manufactured from the plasma of selected donors with high anti-CMV antibody avidity and titers. Expert commentary: Currently available experimental and clinical studies and case reports support the possible effectiveness and safety of HIG infusions in pregnancy for the prevention of congenital CMV disease. The knowledge about the potential efficacy of preventive or therapeutic HIG administration should be enlarged by multi-center randomized studies, which may be favored by the implementation of CMV screening. Meanwhile, if ultrasound examinations show signs of fetal injury, or CMV is detected in the amniotic fluid, the patients should be advised about the possible option of HIG therapy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "a Pediatric School , University of L'Aquila , L'Aquila , Italy."
          },
          {
            "Identifier": [],
            "Affiliation": "b Non-profit Onlus CMV Association Mother to Infant Cytomegalovirus Infection (AMICI) , Rome , Italy."
          }
        ],
        "LastName": "Nigro",
        "ForeName": "Giovanni",
        "Initials": "G"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Rev Anti Infect Ther",
    "NlmUniqueID": "101181284",
    "ISSNLinking": "1478-7210"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunoglobulins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunoglobulins, Intravenous"
    },
    {
      "RegistryNumber": "129L90A25N",
      "NameOfSubstance": "cytomegalovirus-specific hyperimmune globulin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Amniocentesis"
    },
    {
      "QualifierName": [
        "chemistry",
        "virology"
      ],
      "DescriptorName": "Amniotic Fluid"
    },
    {
      "QualifierName": [
        "isolation & purification",
        "therapeutic use"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "immunology",
        "pathogenicity"
      ],
      "DescriptorName": "Cytomegalovirus"
    },
    {
      "QualifierName": [
        "diagnosis",
        "prevention & control",
        "transmission",
        "virology"
      ],
      "DescriptorName": "Cytomegalovirus Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "diagnosis",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "Fetal Diseases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunization, Passive"
    },
    {
      "QualifierName": [
        "isolation & purification",
        "therapeutic use"
      ],
      "DescriptorName": "Immunoglobulins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunoglobulins, Intravenous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Infant, Newborn"
    },
    {
      "QualifierName": [
        "prevention & control"
      ],
      "DescriptorName": "Infectious Disease Transmission, Vertical"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Practice Guidelines as Topic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pregnancy"
    },
    {
      "QualifierName": [
        "diagnosis",
        "virology"
      ],
      "DescriptorName": "Pregnancy Complications, Infectious"
    }
  ]
}